Clinical Trial

Immune Tumor Stroma Factors and Pathologic Complete Response After Neoadjuvant Chemotherapy in Early Breast Cancer

Study acronym: AKRA
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This prospective cohort study aims to identify immune-related predictive factors of response to neoadjuvant chemotherapy in patients with early breast cancer. The study will evaluate immune markers in tumor stroma and blood samples collected before treatment to determine their association with complete pathological remission (pCR). In addition, circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) will be analyzed to explore their correlation with treatment response. The results may contribute to improved selection of patients who are most likely to benefit from neoadjuvant chemotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-06.
Trial Details
NCT Number NCT07407244
Lead Sponsor Institute of Oncology Ljubljana
Conditions Breast Cancer
Enrollment 268 participants
Start Date 2017-03-01
Primary Completion 2017-03-31 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-17